The FDA cleared Medtronic’s Hugo robotic‑assisted surgery (RAS) system and CMR Surgical’s Versius Plus system, expanding U.S. options for hospitals investing in soft‑tissue robotic platforms. These approvals introduce competition to the dominant incumbent and provide institutions greater choice for capital procurement and clinical rollout. Regulatory clearance is expected to accelerate clinical adoption and sales cycles, with both companies highlighting system capabilities, integration pathways, and training programs. Hospital groups evaluating robotic scale‑up will now weigh platform differentiation, service models, and interoperability in procurement decisions.